BioNova Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
BioNova Pharma General Information
Description
Manufacturer of innovative drugs designed to advance clinical treatment for cancer and life-threatening diseases. The company offers a robust pipeline built on proprietary R&D, international collaborations, and advanced biotechnologies, enabling patients in China and worldwide to access novel medicines.
Contact Information
Website
www.bionovapharma.comCorporate Office
- Room 901, Building B, Changtai Plaza, Lane 2889
- Jinke Road, Pudong New Area
- Shanghai, 201203
- China
Corporate Office
- Room 901, Building B, Changtai Plaza, Lane 2889
- Jinke Road, Pudong New Area
- Shanghai, 201203
- China
BioNova Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 3. Early Stage VC (Series B1) | 23-Nov-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 17-Aug-2020 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 25-Dec-2018 | Completed | Startup |
BioNova Pharma Patents
BioNova Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025180390-A1 | Mta-cooperative prmt5 inhibitor compound having tetracyclic fused-ring structure | Pending | 27-Feb-2024 | ||
| CA-3239857-A1 | Carbonyl substituted diazaspiro compounds and its use | Pending | 03-Dec-2021 | ||
| US-20240317748-A1 | Carbonyl substituted diazaspiro compounds and its use | Active | 03-Dec-2021 | ||
| WO-2023098876-A1 | Carbonyl substituted diazaspiro compounds and its use | Inactive | 03-Dec-2021 | ||
| WO-2022228302-A1 | Heteroaromatic carboxamide compounds and its use | Inactive | 25-Apr-2021 | A61K45/06 |
BioNova Pharma Signals
BioNova Pharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| GP Capital (Shanghai) | PE/Buyout | Minority | ||
| Hanne Capital | Growth/Expansion | Minority | ||
| Rencent Capital | Venture Capital | Minority | ||
| BioTrack Capital | Venture Capital | Minority | ||
| LAV (Lilly Asia Fund) | Corporate Venture Capital | Minority |
BioNova Pharma Investments (1)
BioNova Pharma’s most recent deal was a Joint Venture with BK Pharmaceuticals. The deal was made on 07-Nov-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BK Pharmaceuticals | 07-Nov-2019 | Joint Venture | Pharmaceuticals |
BioNova Pharma FAQs
-
When was BioNova Pharma founded?
BioNova Pharma was founded in 2018.
-
Where is BioNova Pharma headquartered?
BioNova Pharma is headquartered in Shanghai, China.
-
What is the size of BioNova Pharma?
BioNova Pharma has 4 total employees.
-
What industry is BioNova Pharma in?
BioNova Pharma’s primary industry is Drug Discovery.
-
Is BioNova Pharma a private or public company?
BioNova Pharma is a Private company.
-
What is BioNova Pharma’s current revenue?
The current revenue for BioNova Pharma is .
-
Who are BioNova Pharma’s investors?
GP Capital (Shanghai), Hanne Capital, Rencent Capital, BioTrack Capital, and LAV (Lilly Asia Fund) are 5 of 9 investors who have invested in BioNova Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process